Letter on 'Idarucizumab for the reversal of dabigatran in patients undergoing heart transplantation'

Eur J Heart Fail. 2019 Jun;21(6):818. doi: 10.1002/ejhf.1446. Epub 2019 Feb 27.

Authors

Eran Kalmanovich¹, Philippe Gaudard², François Roubille^{1

3}

Affiliations

¹ Department of Cardiology, Montpellier University Hospital, Montpellier, France.
² Department of Anesthesiology and Critical Care Medicine, PhyMedExp, Université de Montpellier, INSERM, CNRS, CHU de Montpellier, Montpellier, France.
³ Cardiology Department, PhyMedExp, Université de Montpellier, INSERM, CNRS, CHU de Montpellier, Montpellier, France.

PMID: 30815956
DOI: 10.1002/ejhf.1446

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized
Antithrombins
Dabigatran
Heart Failure*
Heart Transplantation*
Humans

Substances

Antibodies, Monoclonal, Humanized
Antithrombins
idarucizumab
Dabigatran